Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant durvalumab with CD8+ T-cell imaging in resectable NSCLC
NL-OMON48406Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Radboud University Medical Center. Primary endpoints: Feasibility of neoadjuvant durvalumab and Safety of neoadjuvant durvalumab. Started Sep 2019; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON48406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48406.